For patients with IIH, sustainable weight loss offers the most effective and lasting relief from symptoms—and can help ...

Pulmonary hypertension (PH) describes heterogeneous population of patients with a mean pulmonary arterial pressure >20 mm Hg. Rarely, PH presents as a primary disorder but is more commonly part of ...

The initial report of monotherapy with the BCL-2 inhibitor venetoclax showed it had durable clinical activity and favorable ...

Pseudoportomesenteric hypertension (PPMH) is a rare form of non-cirrhotic portal hypertension caused by increased pressure in the portal and mesenteric venous systems. Unlike traditional portal ...

Shares of CRISPR Therapeutics CRSP have risen 14% over the past month, likely driven by encouraging results from the first ...

Hypertension affects a significant proportion of the adult and aging population and represents an important risk factor for vascular cognitive impairment and late-life dementia. Chronic high blood ...

Essential hypertension develops without an identifiable cause and can be chalked up to lifestyle habits, genetics, or age. It could be mild, moderate, or severe in people who develop the condition. If ...

In this conversation, Duke University's Anna Tharakan, lead project manager on Closing the Gap on Hypertension Disparities, and Bradi Granger, Ph.D., research professor at Duke University School of ...

A 24-year-old man presented with a 7-year history of recurrent melena, acutely worsening 3 days prior. He had undergone endoscopic band ligation and glue sclerotherapy for gastro-oesophageal varices, ...

Your blood pressure can rise after exercise, but the increase is typically temporary. Extreme spikes or drops in blood pressure may be a sign of a medical condition such as hypertension. According ...

Background Pulmonary hypertension (PH) is a progressive cardiopulmonary condition associated with increased morbidity and mortality. The extracellular matrix component hyaluronan (HA) is linked to ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today two-year follow-up data from the Phase III STARGLO study. After a median ...